Oragenics Acquires Noachis Terra Inc.

Oragenics Acquires Odyssey Health Neurological Drug Assets

January 2, 2024

Pharmaceuticals

Oragenics, Inc. completed the acquisition of Odyssey Health, Inc.'s neurological drug therapy assets, including ONP-002, ONP-001 rights, a proprietary intranasal delivery device and related formulations. Odyssey retained its remaining assets and operations; Michael Redmond (former Odyssey CEO) was named President of Oragenics to oversee integration and advancement of the neurology pipeline as Oragenics prepares for Phase 2 studies of ONP-002.

Roche Acquires Poseida Therapeutics

November 28, 2024

Biotechnology

Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

Novo Integrated Sciences / Novo Healthnet Acquire Acenzia Inc.

June 29, 2021

Pharmaceuticals

Novo Integrated Sciences, through its wholly owned subsidiary Novo Healthnet Limited, completed the acquisition of Acenzia Inc., a Windsor, Ontario-based nutraceutical manufacturer and diagnostics developer. The all-share transaction closed on June 24, 2021 and is valued at $14,884,039; Novo said the purchase will give it direct control of development, manufacturing and distribution of wellness products and personalized diagnostics.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Ajinomoto Co., Inc. Acquires Forge Biologics

November 13, 2023

Biotechnology

Ajinomoto Co., Inc. will acquire Forge Biologics in an all-cash transaction valued at $620 million, expanding Ajinomoto's gene therapy and plasmid/AAV manufacturing capabilities. Forge, a Columbus, Ohio–based viral vector and plasmid CDMO with a 200,000 sq ft cGMP facility and ~300+ employees, will become a consolidated subsidiary to accelerate global gene and cell therapy manufacturing capacity.

Tilia Holdings Acquires NutriScience Innovations

May 4, 2021

Food & Beverage

Chicago-based private equity firm Tilia Holdings completed the acquisition of NutriScience Innovations, a Milford, Connecticut developer and supplier of branded nutritional and specialty ingredients. The sellers on the transaction included Akoya Capital, Lakeview Equity Partners and Greyrock Capital Group; NutriScience's CEO Alan Yengoyan will remain in his role to support the company's next phase of growth.